SCYX

SCYX

SCYNEXIS Inc. Common Stock

$0.822+-0.000 (-0.000%)

Reaalajas hind

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$0.822

Kõrge

$0.822

Madal

$0.822

Maht

0.05M

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Seotud uudised

GlobeNewswire

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six

Vaata rohkem
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
GlobeNewswire

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh recently

Vaata rohkem
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update